Cargando…

Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial

Fecal microbiota transplantation (FMT) could decolonize multidrug-resistant organisms. We investigated FMT effectiveness and safety in the eradication of carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant enterococci (VRE) intestinal colonization. A prospective non-randomized com...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Jongbeom, Lee, Jung-Hwan, Park, Soo-Hyun, Cha, Boram, Kwon, Kye Sook, Kim, Hyungkil, Shin, Yong Woon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598999/
https://www.ncbi.nlm.nih.gov/pubmed/36289668
http://dx.doi.org/10.3390/biomedicines10102404
_version_ 1784816487273332736
author Shin, Jongbeom
Lee, Jung-Hwan
Park, Soo-Hyun
Cha, Boram
Kwon, Kye Sook
Kim, Hyungkil
Shin, Yong Woon
author_facet Shin, Jongbeom
Lee, Jung-Hwan
Park, Soo-Hyun
Cha, Boram
Kwon, Kye Sook
Kim, Hyungkil
Shin, Yong Woon
author_sort Shin, Jongbeom
collection PubMed
description Fecal microbiota transplantation (FMT) could decolonize multidrug-resistant organisms. We investigated FMT effectiveness and safety in the eradication of carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant enterococci (VRE) intestinal colonization. A prospective non-randomized comparative study was performed with 48 patients. FMT material (60 g) was obtained from a healthy donor, frozen, and administered via endoscopy. The primary endpoint was 1-month decolonization, and secondary endpoints were 3-month decolonization and adverse events. Microbiota analysis of fecal samples was performed using 16S rRNA sequencing. Intention-to-treat analysis revealed overall negative conversion between the FMT and control groups at 1 (26% vs. 10%, p = 0.264) and 3 (52% vs. 24%, p = 0.049) months. The 1-month and 3-month CRE clearance did not differ significantly by group (36% vs. 10%, p = 0.341; and 71% vs. 30%, p = 0.095, respectively). Among patients with VRE, FMT was ineffective for 1-month or 3-month negative conversion (13% vs. 9%, p > 0.999; and 36% vs. 18%, p = 0.658, respectively) However, cumulative overall negative-conversion rate was significantly higher in the FMT group (p = 0.037). Enterococcus abundance in patients with VRE significantly decreased following FMT. FMT may be effective at decolonizing multidrug-resistant organisms in the intestinal tract.
format Online
Article
Text
id pubmed-9598999
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95989992022-10-27 Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial Shin, Jongbeom Lee, Jung-Hwan Park, Soo-Hyun Cha, Boram Kwon, Kye Sook Kim, Hyungkil Shin, Yong Woon Biomedicines Article Fecal microbiota transplantation (FMT) could decolonize multidrug-resistant organisms. We investigated FMT effectiveness and safety in the eradication of carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant enterococci (VRE) intestinal colonization. A prospective non-randomized comparative study was performed with 48 patients. FMT material (60 g) was obtained from a healthy donor, frozen, and administered via endoscopy. The primary endpoint was 1-month decolonization, and secondary endpoints were 3-month decolonization and adverse events. Microbiota analysis of fecal samples was performed using 16S rRNA sequencing. Intention-to-treat analysis revealed overall negative conversion between the FMT and control groups at 1 (26% vs. 10%, p = 0.264) and 3 (52% vs. 24%, p = 0.049) months. The 1-month and 3-month CRE clearance did not differ significantly by group (36% vs. 10%, p = 0.341; and 71% vs. 30%, p = 0.095, respectively). Among patients with VRE, FMT was ineffective for 1-month or 3-month negative conversion (13% vs. 9%, p > 0.999; and 36% vs. 18%, p = 0.658, respectively) However, cumulative overall negative-conversion rate was significantly higher in the FMT group (p = 0.037). Enterococcus abundance in patients with VRE significantly decreased following FMT. FMT may be effective at decolonizing multidrug-resistant organisms in the intestinal tract. MDPI 2022-09-26 /pmc/articles/PMC9598999/ /pubmed/36289668 http://dx.doi.org/10.3390/biomedicines10102404 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shin, Jongbeom
Lee, Jung-Hwan
Park, Soo-Hyun
Cha, Boram
Kwon, Kye Sook
Kim, Hyungkil
Shin, Yong Woon
Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial
title Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial
title_full Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial
title_fullStr Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial
title_full_unstemmed Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial
title_short Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial
title_sort efficacy and safety of fecal microbiota transplantation for clearance of multidrug-resistant organisms under multiple comorbidities: a prospective comparative trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598999/
https://www.ncbi.nlm.nih.gov/pubmed/36289668
http://dx.doi.org/10.3390/biomedicines10102404
work_keys_str_mv AT shinjongbeom efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial
AT leejunghwan efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial
AT parksoohyun efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial
AT chaboram efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial
AT kwonkyesook efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial
AT kimhyungkil efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial
AT shinyongwoon efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial